United Kingdom-based drugmaker Mallinckrodt will acquire Rockville, Md.-based Sucampo Pharmaceuticals for $18 per share. Including Sucampo's debt, the total transaction value is approximately $1.2 billion.
Here are three things to know about the deal.
1. The transaction will add Sucampo's constipation and experimental rare-disease drugs to Mallinckrodt's business.
2. The additions will help diversify Mallinckrodt's products from controversial drugs bringing in most of its revenue, Bloomberg reports. Mallinckrodt's autoimmune and rare disease drug Acthar drew backlash for its high price, while its infant-respiratory drug INOmax lost a September court ruling and may face generic versions.
3. In addition, the Justice Department is probing Mallinckrodt and other opioid drugmakers in an effort to combat the opioid epidemic, the report states.
More articles on supply chain:
Teen inspires Dignity Health CEO to cut plastic straw use across system's 39 hospitals
4 components critical to staff satisfaction
5 latest FDA approvals